Compare JetBlue Airways Corporation (JBLU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? JetBlue Airways Corporation trades at $3.85 (market cap $1.48B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 6.8× JetBlue Airways Corporation's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| JBLU | XBI | |
|---|---|---|
Market Cap | $1.48B | $10.11B |
Volume | 30,275,693 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $6.46 | $169.55 |
52-Week Low | $3.92 | $104.99 |
Typical Hold Time | 44 Days | 38 Days |
Enterprise Value | $8.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.84, down 3.27% today, reflecting ongoing challenges in the airline sector. The stock shows bearish technical signals with negative moving averages and oscillators. Fundamentally, JBLU reported a net loss of $602 million in 2025 with negative profit margins, though revenue remains stable at $9.06 billion. Recent developments include route expansion to Colombia and the launch of BlueFirst premium seating, while activist investor Carl Icahn recently reduced board representation.
The outlook remains challenging with elevated fuel costs and competitive pressures. While the stock trades below book value (P/B 0.93) and analyst consensus target of $5.89, persistent losses and high debt levels pose significant risks. Institutional buying by Bank of America provides some support, but profitability improvement is essential for sustained recovery.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
